Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S29, 2019. DOI: 10.25251/skin.3.supp.29. Disponível em: https://skin.dermsquared.com/skin/article/view/756. Acesso em: 8 jun. 2025.